With the presence of local authorities and partners from Vietnam, Thailand, and South Korea, Biogénesis Bagó has inaugurated its offices in Vietnam, a dedicated space to grow their team and foster closer relationships with clients and partners.

This opening of the regional offices in Vietnam will provide the ability to work collaboratively toward continued expansion in a market where Biogénesis Bagó sees immense potential and opportunities to make a meaningful impact on animal health in the region.

"Having a local base in Vietnam allows us to better understand the specific needs of our clients and respond with tailored biotechnological solutions that address their challenges. This expansion represents a key step in our ongoing mission to support and enhance animal health across Asia, a market we are confident will continue to offer significant growth opportunities," said the CEO of Biogenesis Bago, Mr. Esteban Turic.

The biotechnological company currently has production sites in China and South Korea through key partnerships, as well as technical and commercial teams' representatives in different markets across the region. Last October, their FMD vaccine, Bioaftogen, was launched in the Thai market in collaboration with their partners CVG Tech and Advance Pharma, as well as in the Indonesian market, in November, together with Elanco. This ensures a high-quality solution that will protect animal health, enabling livestock producers to increase productivity and achieve better results.

Asia is an extremely important market for Biogénesis Bagó. The company expects to continue developing the business in different countries in the region, in order to boost productivity and contribute to guaranteeing the animal health status and food security of the region.